Developing 21st Century Medicines
Leading Innovation and Developing Tomorrow’s Medicines™
Developing 21st century genetic medicines requires bold vision and groundbreaking science. At SMDG, we are developing tomorrow’s medicines through proprietary peptide-based therapeutic platforms designed to enable precision delivery of next-generation therapies. Our technologies are being developed to address significant unmet medical needs across rare pediatric, neurodegenerative, inflammatory diseases and oncology.
Learn more about our mission and vision.
You can find further details regarding our work in the journals and publications where our research has been featured and recognized
Inspired by Nature, Engineered to Heal
At SMDG, we are engineering a new generation of targeted, peptide-based therapeutics.
Our proprietary NanoLigand™ platforms are built from engineered peptides that recognize specific biological targets and self-assemble into functional therapeutic nanosystems. These systems enable SMDG to develop targeted medicines incorporating a range of therapeutic agents, including nucleic acids, for diseases where biological barriers limit conventional treatment.
Guided by our Safe-by-Design and Simple-by-Design approach, we are applying decades of pioneering research in nanocarrier design, biological interactions and immune safety to develop precise, potentially disease-modifying therapies for serious diseases with significant unmet medical need.
Pioneering Research
Scientific leadership behind our therapeutic platforms
Professor Moein Moghimi, SMDG’s Co-founder and Chief Science Officer, is the inventor of the NanoLigand™ platforms and an internationally recognized pioneer in nanomedicine, drug delivery and engineering biology.
His research has advanced fundamental understanding of nanocarrier design, interactions with biological systems, complement biology, immune safety and precision delivery. This body of work provides the scientific foundation for SMDG’s peptide-based therapeutic platforms and guides our development of targeted medicines for diseases with significant unmet medical need.
